Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPM31510 with Vitamin K1 in newly diagnosed glioblastoma
NCT04752813Phase 2Active, not recruiting
- Sponsor
- BPGbio
- Start
- Aug 2022
- Primary completion
- Aug 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of ubidecarenone nanodispersion in glioblastoma (GBM), sponsored by BPGbio. Started Aug 2022; status: active, not recruiting.
02
Drugs
ubidecarenone nanodispersion
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04752813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04752813.